Roche Holding Ltd · SIX:RO
Roche — Jefferies Healthcare Conference 2023
15 slides from Roche's conference presentation, Jun 7, 2023
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: 2023 – Jefferies Healthcare Conference
2023 – Jefferies Healthcare Conference Alan Hippe | CFO Roche New York, 7 June 2023
Slide 4: Corporate Executive Committee since April 2023
Corporate Executive Committee since April 2023 Full Pharma R&D value chain represented Pharma Division Diagnostics Division Group Functions Thomas Schinecker CEO Group Theresa Graham Matt Sause Alan Hippe Pharma CEO Diagnostics CEO CFO/CIO Levi Garraway Cris Wilbur Head of Pharma Dev/CMO1 Chief Peop
Slide 5: Q1 2023: Strong underlying sales excluding COVID decline
Q1 2023: Strong underlying sales excluding COVID decline Group sales -3% driven by expected decline in COVID-19 testing (excluding COVID-19: +9%) • Strong Pharma performance (+9%) driven by portfolio rejuvenation (Vabysmo, Ocrevus, Hemlibra, Evrysdi, Tecentriq, Phesgo) • Good Diagnostics base busine
Slide 6: Q1 2023: Group sales decline driven by COVID-19 sales erosion
Q1 2023: Group sales decline driven by COVID-19 sales erosion 2023 2022 Change in % Excl. 1 CHFbn CHFbn CHF CER C19 Pharmaceuticals Division 11.7 11.2 5 9 9 Diagnostics Division 3.6 5.3 -31 -28 4 Roche Group 15.3 16.4 -7 -3 8 CER=Constant Exchange Rates; totals may include differences due to roundin
Slide 7: Q1 2023: Strong underlying growth in Pharma and Diagnostics
Q1 2023: Strong underlying growth in Pharma and Diagnostics Pharma Diagnostics Quarterly sales evolution 2022-2023 Quarterly sales evolution 2022-2023 % CER % CER +30% +30% +24% +20% +20% +7% +8% +10% +9% +9% +3% +4% +10% +10% +6% +4% +9% +0% -2% +3% 0% +0% +2% 0% -10% -4% -9% -10% -6% -20% -28% -20
Slide 8: Q1 2023: Portfolio diversification ongoing
Q1 2023: Portfolio diversification ongoing CHFm -3% at CER Diversification of Roche portfolio +146 +48 Q1 2018 Q1 2023 CHF 13.6bn CHF 15.3bn -1,626 +1,262 -333 -620 16,445 15,322 Diagnostics Neuroscience Oncology Other pharma Hemophilia A Immunology Ophthalmology Infectious diseases AHR Q1 2022 Dia
Slide 9: Portfolio rejuvenation progressing; new launches with >50% of sales
Portfolio rejuvenation progressing; new launches with >50% of sales Columvi (glofitamab): first NME launch in 2023* CHFm % of Pharma Sales*** 7,000 50% 6,000 5,000 42% 4,000 31% 3,000 22% 2,000 1,000 0 Q1 2020 Q1 2021 Q1 2022 Q1 2023 Cotellic Alecensa Tecentriq Ocrevus Hemlibra Luxturna Xofluza Poli
Slide 10: Roche late-stage pipeline
Roche late-stage pipeline 9 NMEs in Phase III: SRP-9001, crovalimab, tiragolumab, giredestrant, inovalisib, divarasib, fenebrutinib, astegolimab, anti-IL6 in ophthalmology Phase III (9 NMEs + 40 AIs) Registration US & EU (1 NME + 3 AIs) RG3502 Kadcyla + T HER-2+ eBC high-risk RG3648 Xolair food alle
Slide 11: Broadest set of technology platforms available
Broadest set of technology platforms available Roche being a pioneer in antibodies, ADCs and bi-specifics 11
Slide 12: Diagnostics: Largest installed base worldwide with significant growth potential
Diagnostics: Largest installed base worldwide with significant growth potential +4% cobas® 4000/6000/80001 +122% cobas® pro / pure +3% Lab SW Solutions +9% Preanalytics / Connectivity HE600 +12% +30% cobas® 5800/6800/8800 BenchMark ULTRA/ ULTRAPLUS +10% +7% LightCycler / MagnaPure DP200/DP600 +29% +
Slide 13: Diagnostics pipeline innovations driving market access in coming years
Diagnostics pipeline innovations driving market access in coming years Mass Spectrometry Next generation sequencing First fully integrated mass spectrometry First end-to-end IVD sequencing solution ● Integration of mass spec into the Core Lab ● Sample in - result out ● Increase patient access to mas
Slide 14: 2023: Update late-stage newsflow
2023: Update late-stage newsflow Pharma Diagnostics Tiragolumab + Tecentriq in 1L PDL1+ NSCLC Glofitamab + GemOx in 2L+ DLBCL Modular transportation system, integrated CCM Vertical into existing cobas connection modules Tiragolumab + Tecentriq + chemo in 1L Lunsumio + Polivy in 2L+ DLBCL* Esophageal
Slide 15: Doing now what patients need next
Doing now what patients need next